

Amendments to the Claims:

This listing of claims shall replace all prior versions and listings of claims.

Listing of Claims

1. (original) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2-10. (canceled)

11. (original): An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12-16. (canceled)

17. (currently amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim [[1]] 11.

18. (canceled)

19. (original): A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20-21. (canceled)

22. (original): A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. (original): The product produced by the method of claim 20.

24. (previously presented) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

25. (currently amended): An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- 25
- (a) a protein ~~comprising~~ consisting of amino acid residues 1 to 272 of SEQ ID NO: 125;
 - (b) a protein consisting of amino acid residues 23 to 32 of SEQ ID NO: 125;
 - (c) a protein consisting of amino acid residues 61 to 68 of SEQ ID NO: 125; and
 - (d) a protein consisting of amino acid residues 141 to 148 of SEQ ID NO:125.

26. (previously presented): The antibody or fragment thereof of claim 25 that specifically binds protein (a).

27. (previously presented): The antibody or fragment thereof of claim 25 that specifically binds protein (b).

28. (previously presented): The antibody or fragment thereof of claim 25 that specifically binds protein (c).

29. (previously presented): The antibody or fragment thereof of claim 25 that specifically binds protein (d).

30. (previously presented): The antibody or fragment thereof of claim 26 which is a human antibody.

31. (previously presented): The antibody or fragment thereof of claim 26 which is a polyclonal antibody.

32. (previously presented): The antibody or fragment thereof of claim 26 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

33. (previously presented): The antibody or fragment thereof of claim 26 which is labeled.

34. (previously presented): The antibody or fragment thereof of claim 33 wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label; and
- (d) a bioluminescent label.

35. (previously presented): The antibody or fragment thereof of claim 26 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

36. (previously presented): The antibody or fragment thereof of claim 26 wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

37. (previously presented): An isolated cell that produces the antibody or fragment thereof of claim 26.

38. (previously presented): A hybridoma that produces the antibody or fragment thereof of claim 26.

39. (currently amended): An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein ~~comprising~~ consisting of amino acid residues 1 to 272 of SEQ ID NO: 125;
- (b) a protein consisting of amino acid residues 23 to 32 of SEQ ID NO: 125;
- (c) a protein consisting of amino acid residues 61 to 68 of SEQ ID NO: 125; and
- (d) a protein consisting of amino acid residues 141 to 148 of SEQ ID NO: 125.

40. (previously presented): The antibody or fragment thereof of claim 39 that specifically binds protein (a).

41. (previously presented): The antibody or fragment thereof of claim 39 that specifically binds protein (b).

42. (previously presented): The antibody or fragment thereof of claim 39 that specifically binds protein (c).

43. (previously presented): The antibody or fragment thereof of claim 39 that specifically binds protein (d).

44. (currently amended): An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein ~~comprising~~ consisting of the complete polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580; and
- (b) a protein consisting of a portion of the polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580, wherein said portion comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580.

45. (previously presented): The antibody or fragment thereof of claim 44 that specifically binds protein (a).

46. (previously presented): The antibody or fragment thereof of claim 44 that specifically binds protein (b).

47. (previously presented): The antibody or fragment thereof of claim 45 which is a human antibody.

48. (previously presented): The antibody or fragment thereof of claim 45 which is a polyclonal antibody.

49. (previously presented): The antibody or fragment thereof of claim 45 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

50. (previously presented): The antibody or fragment thereof of claim 45 which is labeled.

51. (previously presented): The antibody or fragment thereof of claim 45 wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label; and
- (d) a bioluminescent label.

52. (previously presented): The antibody or fragment thereof of claim 45 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

53. (previously presented): The antibody or fragment thereof of claim 45 wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

54. (previously presented): An isolated cell that produces the antibody or fragment thereof of claim 45.

55. (previously presented): A hybridoma that produces the antibody or fragment thereof of claim 45.

56. (currently amended): An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein ~~comprising~~ consisting of the complete polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580; and

(b) a protein consisting of a portion of the polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580, wherein said portion comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the HCE5F43 cDNA contained in ATCC Deposit Number 209580.

57. (previously presented): The antibody or fragment thereof of claim 56 that specifically binds protein (a).

58. (previously presented): The antibody or fragment thereof of claim 56 that specifically binds protein (b).